Ss Pharmaceutical Co., Ltd.

Ssp Co. Ltd

Other

Hisamitsu Pharmaceutical Company, Inc.

Bausch-lomb Incorporated

Katsumi Imamori

Akira Iwasa

Shuichi Kasai

Minoru Okada

Yasuo Ikeda

Kenji Ono

Toshiaki Kurazumi

Kenji Ishigaki

Tetsuo Kaneko

Makoto Suzuki

Takemitsu Asaoka

Takashi Narui

Lyle M Bowman

Yutaka Murata

Hiroyuki Mizuno

Santosh K Chandrasekaran

Akihiro Shibata

Masami Takahashi

Samir Roy

Satoru Enomoto

Hirohisa Okuyama

Syuichi Kasai

Yoshiaki Hanaoka

Masunari Fushimi

Tomohiko Osugi

Shigenori Otsuka

Shinichi Morimoto

Santosh Kumar Chandrasekaran

Liquid drug preparations characterized by containing fudostein and an acid together with a sweetener such as sugar alcohol, trehalose or a sweetener having a high degree of sweetness. These liquid drug preparations are fudostein-containing liquid drug preparations which are free from color change or sedimentation upon prolonged storage and can be easily taken.

Liquid drug preparations

The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Quinolone carboxylic acid compositions and related methods of treatment

An orally administrable uncompressed rapidly dissolving molded dosage form comprises a drug and either one or more saccharides or one saccharide and polyvinylpyrrolidone. Saccarides are chosen and used in proportion based on their solubilities. Methods for producing uncompressed rapidly dissolving solid preparations comprise mixing a drug and carriers according to the present invention and charging the mixture in a mold. Rapidly dissolving oral dosage forms facilitate administration of drugs to patients having a difficulty in swallowing such as children and the elderly.

Quickly soluble solid preparations

This invention relates to an intra-articular preparation for the treatment of arthropathy, which comprises microcapsules of (a) a high-molecular substance, which has biodegradability and biocompatibility, and (b) a drug. When applied directly to a joint area, this preparation can achieve a high drug concentration at the target area, can inhibit occurrence of general side effect, and can maintain drug efficacy over a long term. The preparation can therefore alleviate the burden on the patient.

Intra-articular preparation for the treatment of arthropathy

Drug composition with controlled drug release rate

A hydrophilic adhesive mass contains 0.05 to 10 wt. % of a copolymer of an aminoalkyl (meth)acrylate and an alkyl (meth)acrylate. This hydrophilic adhesive mass is excellent in adhesiveness, and especially when combined with a pharmacologically active ingredient, is suitable for use in providing hydrophilic plasters.

Hydrophilic adhesive masses

An antiinflammatory and analgesic gel preparation comprising diclofenac or its salts, an ester of dibasic acid, a lower alcohol, and a nonionic polymer or a mixture of nonionic polymers selected from the group consisting of (a) 1.5-4% by weight of hydroxypropyl cellulose having a molecular weight of 500,000 or greater, (b) 2-4% by weight of hydroxyethyl cellulose having a molecular weight of 1,250,000 or greater, and (c) 1.5-4% by weight of a mixture of hydroxypropyl cellulose having a molecular weight of 500,000 or greater and hydroxyethyl cellulose having a molecular weight of 1,250,000 or greater, and having a viscosity of 5,000-35,000 cps and an yield value of 5 dyn/cm.sup.2 or greater. The gel preparation is excellent in the percutaneous absorption of diclofenac or its salts and provides good properties upon use and superior medical effects of diclofenac or its salts.

Antiinflammatory and analgesic gel preparation

A pranoprofen-containing, suspending medicinal composition is formed of the following three ingredients (a) to (c):

Pranoprofen-containing, suspending medicinal composition

Antiinflammatory gel preparation

Described herein are antidiarrheal compositions containing loperamide hydrochloride as an effective ingredient and a saccharide, for example, a monosaccharide, oligosaccharide or sugar alcohol in an amount as much as at least 3,000 times the weight of loperamide hydrochloride.

Antidiarrheal compositions containing loperamide hydrochloride and a

Described herein are antidirarrheal compositions containing loperamide hydrochloride as an effective ingredient and a saccharide, for example, a monosaccharide, oligosaccharide or sugar alcohol in an amount as much as at least 3,000 times the weight of loperamide hydrochloride.

Antidiarrheal compositions containing laperamide hydrochloride and a

Ointments are disclosed, which contain (a) 0.05-1 wt. % of deprodone propionate and (b) 89-99.95 wt. % of a base formed of white petroleum and a liquid hydrocarbon. The ointments may additional contain (c) 1-10 wt. % of a polyhydric alcohol.

Corticorsteroid-containing ointments

Antimycotic external imidazole preparations are disclosed. They contain the following ingredients:

Antimycotic external imidazole preparations

Growing community of inventors

Yotsukaido, Japan

Katsumi Imamori